Articles published by Amylyx Pharmaceuticals, Inc.

Amylyx Pharmaceuticals Announces Peer-Reviewed Publication of Phase 2 Open-Label HELIOS Trial Data for AMX0035 in The Journal of Clinical Investigation

May 15, 2026

From Amylyx Pharmaceuticals, Inc.

Via Business Wire

Amylyx Pharmaceuticals Reports First Quarter 2026 Financial Results

May 07, 2026

From Amylyx Pharmaceuticals, Inc.

Via Business Wire

Amylyx Pharmaceuticals to Participate in Upcoming Investor Conferences

May 06, 2026

From Amylyx Pharmaceuticals, Inc.

Via Business Wire

Amylyx Pharmaceuticals Announces U.S. Expanded Access Program for Adults with Post-Bariatric Hypoglycemia

May 05, 2026

From Amylyx Pharmaceuticals, Inc.

Via Business Wire

Amylyx Pharmaceuticals to Report First Quarter 2026 Financial Results on May 7, 2026

April 30, 2026

From Amylyx Pharmaceuticals, Inc.

Via Business Wire

Amylyx Pharmaceuticals to Present at the 25th Annual Needham Virtual Healthcare Conference

April 08, 2026

From Amylyx Pharmaceuticals, Inc.

Via Business Wire

Amylyx Pharmaceuticals Announces Completion of Enrollment in Pivotal Phase 3 LUCIDITY Clinical Trial of Avexitide in Post-Bariatric Hypoglycemia

March 24, 2026

From Amylyx Pharmaceuticals, Inc.

Via Business Wire

Amylyx Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results

March 03, 2026

From Amylyx Pharmaceuticals, Inc.

Via Business Wire

Amylyx Pharmaceuticals to Participate in Upcoming March Investor Conferences

February 26, 2026

From Amylyx Pharmaceuticals, Inc.

Via Business Wire

Amylyx Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on March 3, 2026

February 24, 2026

From Amylyx Pharmaceuticals, Inc.

Via Business Wire

Amylyx Pharmaceuticals Announces Nomination of AMX0318 as a Novel, Long-Acting GLP-1 Receptor Antagonist Development Candidate, Identified in Collaboration with Gubra A/S

January 08, 2026

From Amylyx Pharmaceuticals, Inc.

Via Business Wire

Amylyx Pharmaceuticals Announces New Safety and Tolerability Cohort 1 Data of AMX0114 in ALS from First-in-Human LUMINA Trial

December 05, 2025

From Amylyx Pharmaceuticals, Inc.

Via Business Wire

Amylyx Pharmaceuticals Reports Third Quarter 2025 Financial Results

November 06, 2025

From Amylyx Pharmaceuticals, Inc.

Via Business Wire

Amylyx Pharmaceuticals to Present at Upcoming Investor Conferences

November 03, 2025

From Amylyx Pharmaceuticals, Inc.

Via Business Wire

Amylyx Pharmaceuticals to Report Third Quarter 2025 Financial Results on November 6, 2025

October 30, 2025

From Amylyx Pharmaceuticals, Inc.

Via Business Wire

Amylyx Pharmaceuticals Announces Pricing of $175 Million Underwritten Public Offering of Common Stock

September 10, 2025

From Amylyx Pharmaceuticals, Inc.

Via Business Wire

Amylyx Pharmaceuticals Announces Proposed Public Offering of Common Stock

September 09, 2025

From Amylyx Pharmaceuticals, Inc.

Via Business Wire

Amylyx Pharmaceuticals to Discontinue ORION Program of AMX0035 for Progressive Supranuclear Palsy (PSP)

August 27, 2025

From Amylyx Pharmaceuticals, Inc.

Via Business Wire

Amylyx Pharmaceuticals to Participate in Upcoming Investor Conferences

August 26, 2025

From Amylyx Pharmaceuticals, Inc.

Via Business Wire

Amylyx Pharmaceuticals Reports Second Quarter 2025 Financial Results

August 07, 2025

From Amylyx Pharmaceuticals, Inc.

Via Business Wire

Amylyx Pharmaceuticals to Report Second Quarter 2025 Financial Results on August 7, 2025

July 31, 2025

From Amylyx Pharmaceuticals, Inc.

Via Business Wire

Amylyx Pharmaceuticals Presents New Exploratory Analyses from Phase 2 and Phase 2b Clinical Trials of Avexitide in Post-Bariatric Hypoglycemia at ENDO 2025

July 13, 2025

From Amylyx Pharmaceuticals, Inc.

Via Business Wire

Amylyx Pharmaceuticals to Host Event to Discuss Post-bariatric Hypoglycemia and Avexitide at ENDO 2025

July 08, 2025

From Amylyx Pharmaceuticals, Inc.

Via Business Wire

Amylyx Pharmaceuticals Receives U.S. FDA Fast Track Designation for AMX0114 for the Treatment of Amyotrophic Lateral Sclerosis

June 03, 2025

From Amylyx Pharmaceuticals, Inc.

Via Business Wire

Amylyx Pharmaceuticals to Participate in Upcoming June Investor Conferences

May 21, 2025

From Amylyx Pharmaceuticals, Inc.

Via Business Wire

Amylyx Pharmaceuticals Announces Positive Long-Term Results from Phase 2 HELIOS Clinical Trial of AMX0035 in People with Wolfram Syndrome

May 12, 2025

From Amylyx Pharmaceuticals, Inc.

Via Business Wire

Amylyx Pharmaceuticals Reports First Quarter 2025 Financial Results

May 08, 2025

From Amylyx Pharmaceuticals, Inc.

Via Business Wire

Amylyx Pharmaceuticals to Participate in Upcoming May Investor Conferences

May 07, 2025

From Amylyx Pharmaceuticals, Inc.

Via Business Wire

Amylyx Pharmaceuticals to Report First Quarter 2025 Financial Results on May 8, 2025

May 01, 2025

From Amylyx Pharmaceuticals, Inc.

Via Business Wire

Amylyx Pharmaceuticals Announces First Participant Dosed in Pivotal Phase 3 LUCIDITY Trial of Avexitide in Post-Bariatric Hypoglycemia

April 30, 2025

From Amylyx Pharmaceuticals, Inc.

Via Business Wire

< Previous 1 2 3 4 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.